AgingNCT07523061
PrecisionAge Pilot Study
A study testing multimodal lifestyle intervention: in people with Aging, run by Heike A. Bischoff-Ferrari, Prof. Dr. med., DrPH at 1 site in Switzerland.
Trial summary
This is a pilot trial to test the feasibility of a multimodal lifestyle intervention (physical activity, mindfulness, sleep routines, calorie-restricted Mediterranean diet, supplements: vitamin D, omega-3, Multivitamin-mineral Centrum50+®, plant-based-supplement Fruitflow®) in preparation of a larger clinical trial. Read more about this study
- Who is it for?
- Ages 55 to 70 years
- Conditions the study is for
- Aging
- What is being tested?
- multimodal lifestyle intervention:
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteSwitzerland
- Study dates
- 10 Apr 2026to 30 Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Community-dwelling women and men (sex) aged between 55 and 70 years
- low daily exercise (i.e. <4000 steps/day on average in the last month, self-assessment)
- low fruit and vegetable intake (< 3 per day)
- at risk for accelerated functional and biological aging based on the following criteria:
- overweight (BMI between 25.0 and 29.9)
- at least one of the following lab values or at least borderline blood pressure within the mentioned range:
Show all 14Show fewer
- HbA1c 5.7 - 6.4% (pre-diabetes)
- LDL 3.4 - 4.1 mmol L-¹ or TG > 1.7 mmol L-¹ (atherogenesis)
- hs-CRP 2 - 3 mg L-¹ (low-grade inflammation)
- increase in BP or borderline BP (SBP 130 - 139 / DBP 85 - 89 mmHg)
- availability of a smartphone and agrees that it can be used to connect the activity tracker to the internet and consent that data from the activity tracker will be uploaded and analyzed
- Ability to communicate, read and write in German
- Dietary tolerability of a Mediterranean diet (e.g. vegetables, olive oil, white meat, fish, plant-based proteins)
- Ability to swallow supplement capsules
Who cannot join
- current smoking or vaping (smoker = More than 100 cigarettes or vapes in a life-time OR quitted less than 15 years ago and smoked more than 8 pack-years OR quitted less than 10 years ago and smoked max. 8 pack-years)
- current supplementation with vitamin D and/or omega-3 and/or Fruitflow® and/or Centrum Silver® Adults 50+ multivitamin and/or taking any other multi-vitamin preparate and not willing to forgo during the trial duration
- prior (ever used for more than 3 months) or current intake/application of metformin and/or GLP-1 and/or SGLT-2-inhibitor.
- Current or recent (previous 12 months) participation in another clinical trial, or plans of such participation during participation in this trial
- Presence of the following diagnosed health conditions in the last 4 years:
- cancer (except non-melanoma skin cancer)
Show all 12Show fewer
- myocardial infarction, stroke, transient ischemic attack, angina pectoris, or coronary artery intervention
- renal impairment and/or liver disease
- relevant/severe impairment in mobility that leads to an inability to participate in the exercise component
- major visual or hearing impairment
- other serious illness that would preclude participation in the intervention components
- Living together with another study participant
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
Universitäre Altersmedizin Felix Platter
Basel, Canton of Basel-City, 4055
About this study
This is a pilot trial to test the feasibility of a multimodal lifestyle intervention (physical activity, mindfulness, sleep routines, calorie-restricted Mediterranean diet, supplements: vitamin D, omega-3, Multivitamin-mineral Centrum50+®, plant-based-supplement Fruitflow®) in preparation of a larger clinical trial.
- Conditions
- Aging
- Being tested
- multimodal lifestyle intervention:
- Keywords
- pilot trial, accelerated aging, precision age, multimodal intervention
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
multimodal lifestyle intervention:Other
- personalized physical activity program including strength, endurance, and mindfulness components plus instruction to reduce sedentary behavior and improve sleep;
- personalized Mediterranean, calorie-reduced diet recommendation;
- intake of nutritional supplements: 2'000 IU/d of vitamin D (incl. multivitamin), 1g/d of omega-3 fatty acids, Centrum Silver® Adults 50+ 1 tbl/d, Fruitflow® 150 mg/d (plant-based extract from tomatoes)
| Study group | Role | What they receive |
|---|---|---|
| multimodal intervention | Active comparator | Not described Receives: Other: multimodal lifestyle intervention: |
| control | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility: eligibility rate
Proportion of screened individuals who meet Inclusion/Exclusion Criteria (eligibility rate), and the most common reasons for ineligibility by criterion
Measured: baseline
Feasibility: recruitment rate
Recruitment rate (participants enrolled per week) and total time required to enroll n=10
Measured: baseline
Feasibility: enrollment rate
Proportion of eligible individuals who provide consent and are enrolled
Measured: baseline
Feasibility: Retention
Proportion of enrolled participants who complete the Day 14 visit
Measured: 14 days
Feasibility: drop-out rate
Proportion of enrolled participants who withdraw prior to Day 14, with reasons for withdrawal summarized
Measured: 14 days
Feasibility: assessment completion rate
Completion rate for each major assessment at Baseline and Day 14 (6-minute Walk Test (6MWT), knee extensor muscle strength measurements, Cambridge Neuropsychological Test Automated Battery (CANTAB®)), including the proportion with valid/usable results
Measured: 14 days
Feasibility: data completeness (proportion with complete primary endpoint data at Day 14)
Data completeness for the overall assessment battery at Day 14 (proportion with complete primary endpoint data at Day 14), with documentation of missingness reasons (participant burden, scheduling, technical failure, etc.)
Measured: 14 days
Feasibility: acceptability of study
Participant-reported acceptability of study procedures by Day 14 (brief questionnaire or structured feedback)
Measured: 14 days
Feasibility: willingness to participate in a longer trial
Proportion of participants indicating willingness to participate in a longer (e.g., 1-year) trial using the same or similar procedures
Measured: 14 days
Safety/tolerability: serious adverese events
Proportion experiencing any adverse event by Day 14
Measured: 14 days
Safety/tolerability: related serious adverese events
Proportion considered related to interventions
Measured: 14 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2026
- Study start10 Apr 2026
- Primary completion30 Jun 2026 (estimated)
- Study completion30 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Heike A. Bischoff-Ferrari, Prof. Dr. med., DrPH
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Heike A. Bischoff-Ferrari, Prof. Dr. med., DrPH, University of Zurich
- Investigators
- Heike A Bischoff-Ferrari, Prof. Dr. med., DrPH, Principal investigator, Universitäre Altersmedizin Felix Platter
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07523061
- Sponsor's protocol ID
- EKNZ_2026-00476
- Status last verified
- Jun 2026
- First submitted
- 30 Mar 2026
- Last updated
- 30 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PrecisionAge Pilot Study
- ClinicalTrials.gov ID
- NCT07523061
- Acronym / sponsor ID
- EKNZ_2026-00476
- Conditions
- Aging
- Keywords
- pilot trial, accelerated aging, precision age, multimodal intervention
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- Heike A. Bischoff-Ferrari, Prof. Dr. med., DrPHUniversity, hospital or other
- Study start
- 10 Apr 2026 (actual)
- Primary completion
- 30 Jun 2026 (estimated)
- Study completion
- 30 Jun 2026 (estimated)
- First posted
- 13 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a pilot trial to test the feasibility of a multimodal lifestyle intervention (physical activity, mindfulness, sleep routines, calorie-restricted Mediterranean diet, supplements: vitamin D, omega-3, Multivitamin-mineral Centrum50+®, plant-based-supplement Fruitflow®) in preparation of a larger clinical trial.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| multimodal intervention | Active comparator | Other: multimodal lifestyle intervention: |
| control | No intervention | – |
Who may qualify
- Ages
- 55 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- Community-dwelling women and men (sex) aged between 55 and 70 years
- low daily exercise (i.e. <4000 steps/day on average in the last month, self-assessment)
- low fruit and vegetable intake (< 3 per day)
- at risk for accelerated functional and biological aging based on the following criteria:
- overweight (BMI between 25.0 and 29.9)
Key exclusion criteria (12 listed)
- current smoking or vaping (smoker = More than 100 cigarettes or vapes in a life-time OR quitted less than 15 years ago and smoked more than 8 pack-years OR quitted less than 10 years ago and smoked max. 8 pack-years)
- current supplementation with vitamin D and/or omega-3 and/or Fruitflow® and/or Centrum Silver® Adults 50+ multivitamin and/or taking any other multi-vitamin preparate and not willing to forgo during the trial duration
- prior (ever used for more than 3 months) or current intake/application of metformin and/or GLP-1 and/or SGLT-2-inhibitor.
- Current or recent (previous 12 months) participation in another clinical trial, or plans of such participation during participation in this trial
- Presence of the following diagnosed health conditions in the last 4 years:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| multimodal lifestyle intervention:* personalized physical activity program including strength, endurance, and mindfulness components plus instruction to reduce sedentary behavior and improve sleep; * personalized Mediterranean, calorie-reduced diet recommendation; * intake of nutritional supplements: 2'000 IU/d of vitamin D (incl. multivitamin), 1g/d of omega-3 fatty acids, Centrum Silver® Adults 50+ 1 tbl/d, Fruitflow® 150 mg/d (plant-based extract from tomatoes) | Other | multimodal intervention |
Primary outcome
Feasibility: eligibility rate
Time frame: baseline
Proportion of screened individuals who meet Inclusion/Exclusion Criteria (eligibility rate), and the most common reasons for ineligibility by criterion
Feasibility: recruitment rate
Time frame: baseline
Recruitment rate (participants enrolled per week) and total time required to enroll n=10
Feasibility: enrollment rate
Time frame: baseline
Proportion of eligible individuals who provide consent and are enrolled
Feasibility: Retention
Time frame: 14 days
Proportion of enrolled participants who complete the Day 14 visit
Feasibility: drop-out rate
Time frame: 14 days
Proportion of enrolled participants who withdraw prior to Day 14, with reasons for withdrawal summarized
Feasibility: assessment completion rate
Time frame: 14 days
Completion rate for each major assessment at Baseline and Day 14 (6-minute Walk Test (6MWT), knee extensor muscle strength measurements, Cambridge Neuropsychological Test Automated Battery (CANTAB®)), including the proportion with valid/usable results
Feasibility: data completeness (proportion with complete primary endpoint data at Day 14)
Time frame: 14 days
Data completeness for the overall assessment battery at Day 14 (proportion with complete primary endpoint data at Day 14), with documentation of missingness reasons (participant burden, scheduling, technical failure, etc.)
Feasibility: acceptability of study
Time frame: 14 days
Participant-reported acceptability of study procedures by Day 14 (brief questionnaire or structured feedback)
Feasibility: willingness to participate in a longer trial
Time frame: 14 days
Proportion of participants indicating willingness to participate in a longer (e.g., 1-year) trial using the same or similar procedures
Safety/tolerability: serious adverese events
Time frame: 14 days
Proportion experiencing any adverse event by Day 14
Safety/tolerability: related serious adverese events
Time frame: 14 days
Proportion considered related to interventions
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Aging
Recruiting
Ultraformer MPT Combined With Fractional CO2 Versus Fractional CO2 Alone for Facial Rejuvenation
Skin Aging
Active, not recruiting
Iterative Design Trial to Assess Dietary Supplements and Other Aging-targeted Therapies
Aging, Longevity
RecruitingObservational study
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
Aging
Not yet recruitingObservational study
Biological Aging Following Full-Arch Implant-Supported Fixed Rehabilitation in Edentulous Patients
Edentulism, Biological Aging
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Heike A Bischoff-Ferrari, Prof. Dr. med., DrPH principal investigator
Universitäre Altersmedizin Felix Platter
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing multimodal lifestyle intervention: in people with Aging, run by Heike A. Bischoff-Ferrari, Prof. Dr. med., DrPH at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 30 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility: eligibility rate (time frame: baseline). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2026.